Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle

Novo Nordisk and Pfizer are locked in a $10 billion bidding war for U.S. biotech Metsera's obesity drug assets, with Pfizer reportedly matching Novo's superior offer after its initial $7.3 billion agreement. This intense competition underscores the strategic importance of Metsera's next-generation GLP-1 weight-loss treatments in the rapidly expanding obesity drug market, projected to reach $150 billion, as both pharmaceutical giants vie for market dominance amidst legal challenges and regulatory scrutiny.

Analysis

Novo Nordisk and Pfizer are locked in a $10 billion bidding war for U.S. biotech Metsera's obesity drug assets, specifically its next-generation GLP-1 weight-loss treatments. This intense competition underscores the strategic importance of the obesity drug market, which analysts project to reach $150 billion early next decade. Metsera shares surged 10% on Thursday and are up 50% since Novo's initial unsolicited bid, reflecting the perceived value of its assets.

Pfizer, initially holding a $7.3 billion agreement from September, reportedly matched Novo's superior $10 billion offer, indicating a strong desire to enter this lucrative market. Novo Nordisk, seeking to recover market share lost to Eli Lilly, is aggressively pursuing the acquisition, with its offer set to expire on Thursday morning. The bidding war has positively impacted both Pfizer (+0.9%) and Novo Nordisk (+1.5%) stock prices, despite the significant capital outlay.

The acquisition process is fraught with legal and regulatory challenges, including an FTC warning letter questioning Novo's two-step acquisition plan and Pfizer's claims of regulatory pushback against Novo's bid. This litigation and antitrust scrutiny introduce uncertainty into the deal's finalization, despite the high valuation and strategic imperative for both pharmaceutical giants.

Key Decisions for Investors

• Monitor the definitive outcome of the Metsera bidding war, as the acquiring entity and final deal structure will significantly influence the obesity drug market's competitive landscape.
• Assess the ongoing legal and regulatory challenges, including FTC scrutiny, which introduce execution risk and could impact the timeline or ultimate feasibility of the acquisition for either bidder.
• Evaluate the strategic implications for both Novo Nordisk and Pfizer, considering the substantial investment required against the long-term growth potential in the projected $150 billion obesity drug market.